AstraZeneca verdict from England: trials on children suspended

EMA announced another side effect of AstraZeneca / Oxford corona virus vaccine: Escape syndrome – Health News

The European Medicines Agency (EMA) announced that five people with the AstraZeneca / Oxford corona virus vaccine had identified another potentially dangerous blood-related health problem: Escape syndrome.

However, the data also showed that the UK Medicines and Healthcare Products Regulatory Authority (MHRA) detected three cases of escape syndrome out of 20 million people given the AstraZeneca vaccine by late March.


According to the Mayo Clinic, one of the largest hospitals in the USA, due to the systematic capillary leak syndrome, also called escape syndrome, blood volume and blood pressure drop as fluid exits the bloodstream. This can deprive tissues in the kidneys, brain and liver of the oxygen and nutrients they need for their normal functioning. If the condition is not treated, it can lead to organ failure or even death.

Usually a day or two before the “episodes” of the systemic capillary leak syndrome, one encounters one or more nonspecific symptoms. Among these symptoms are the following;



Abdominal pain


-Muscle pains,

– Artan susama,

Sudden increase in body weight


On the other hand, the capillary leak syndrome link represents another potential blow for AstraZeneca, following reports of rare blood clots in the brain and abdomen. However, authorities insist that there is no evidence that the vaccine caused blood conditions.

On the other hand, EMA recently revealed that Johnson and Johnson, using the same technology as the AstraZeneca / Oxford vaccine, also reviewed the blood clotting reports containing the Covid vaccine. Johnson & Johnson and AstraZenaca / Oxford’s vaccines contain an adenovirus that causes some common colds to create antibodies against the corona virus.

Johnson & Johnson’s corona virus vaccine, produced by Janssen, the Belgian branch of the US company, was allocated to young people by the British authorities because it was given as a single dose. The vaccine has been approved in the EU and would be available in the coming months. The statement made by the EMA said, “At this stage, it is not yet clear whether there is a causal relationship between both vaccines and the conditions reported.” .

J&J said it is aware of blood clot reports and is working with regulators to evaluate data and provide relevant information. In the statement made by the company, “Currently, there is no clear causal relationship between these rare events and the Johnson & Johnson Covid vaccine” expressions were used.


On the other hand, EMA announced yesterday that the link between the AstraZeneca / Oxford vaccine and blood clots is possible, but underlined that the benefits of the vaccine still outweigh the risks. The EMA’s safety committee noted that unusual blood clots with low platelets should be listed as the very rare side effects of the AstraZeneca vaccine.

On the other hand, a dozen EU countries have suspended the use of the AstraZeneca / Oxford vaccine or banned it from being administered under certain age groups. For example, England stated that this vaccine cannot be given to those under the age of 30 and the Netherlands to those under 60.


Download the NTV application, be informed about the developments

Leave a Reply

Your email address will not be published. Required fields are marked *